IL173065A - USE OF c-dI-GMP OR A CYCLIC DINUCLEOTIDE ANALOGUE THEREOF IN THE MANUFACTURE OF A MEDICAMENT, - Google Patents

USE OF c-dI-GMP OR A CYCLIC DINUCLEOTIDE ANALOGUE THEREOF IN THE MANUFACTURE OF A MEDICAMENT,

Info

Publication number
IL173065A
IL173065A IL173065A IL17306506A IL173065A IL 173065 A IL173065 A IL 173065A IL 173065 A IL173065 A IL 173065A IL 17306506 A IL17306506 A IL 17306506A IL 173065 A IL173065 A IL 173065A
Authority
IL
Israel
Prior art keywords
gmp
biofilm
microbial
colonization
aureus
Prior art date
Application number
IL173065A
Other languages
English (en)
Other versions
IL173065A0 (en
Original Assignee
David K R Karaolis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by David K R Karaolis filed Critical David K R Karaolis
Publication of IL173065A0 publication Critical patent/IL173065A0/en
Publication of IL173065A publication Critical patent/IL173065A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
IL173065A 2003-07-28 2006-01-10 USE OF c-dI-GMP OR A CYCLIC DINUCLEOTIDE ANALOGUE THEREOF IN THE MANUFACTURE OF A MEDICAMENT, IL173065A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49002903P 2003-07-28 2003-07-28
PCT/US2004/023498 WO2005030186A2 (en) 2003-07-28 2004-07-22 Method for attenuating virulence of microbial pathogens and for inhibiting microbial biofilm formation

Publications (2)

Publication Number Publication Date
IL173065A0 IL173065A0 (en) 2006-06-11
IL173065A true IL173065A (en) 2011-05-31

Family

ID=34392905

Family Applications (1)

Application Number Title Priority Date Filing Date
IL173065A IL173065A (en) 2003-07-28 2006-01-10 USE OF c-dI-GMP OR A CYCLIC DINUCLEOTIDE ANALOGUE THEREOF IN THE MANUFACTURE OF A MEDICAMENT,

Country Status (7)

Country Link
US (1) US8367716B2 (https=)
EP (1) EP1651242A2 (https=)
JP (1) JP2007500697A (https=)
AU (1) AU2004275696B2 (https=)
CA (1) CA2533873A1 (https=)
IL (1) IL173065A (https=)
WO (1) WO2005030186A2 (https=)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1729781B1 (en) * 2004-03-15 2012-10-24 Karaolis, David K. R. A method for inhibiting cancer cell proliferation or increasing cancer cell apoptosis
WO2006073514A2 (en) * 2004-08-25 2006-07-13 Tufts University Compositions, methods and kits for repressing virulence in gram positive bacteria
EP1782826A1 (en) * 2005-11-08 2007-05-09 GBF Gesellschaft für Biotechnologische Forschung mbH PQS and c-diGMP and its conjugates as adjuvants and their uses in pharmaceutical compositions
US8343536B2 (en) 2007-01-25 2013-01-01 Cook Biotech Incorporated Biofilm-inhibiting medical products
CN101801521B (zh) 2007-05-14 2015-06-17 纽约州立大学研究基金会 生物膜中细菌细胞内的生理学分散响应诱导
WO2009100456A2 (en) * 2008-02-08 2009-08-13 Prothera, Inc. Inhibition and treatment of gastrointestinal biofilms
WO2009133560A1 (en) * 2008-04-29 2009-11-05 Smart Assays Non-hydrolyzable and permeable cyclic bis-[nucleotide monophosphate] derivatives and uses thereof
US20120178710A1 (en) * 2009-07-01 2012-07-12 Rutgers, The State University Of New Jersey Synthesis of cyclic diguanosine monophosphate and thiophosphate analogs thereof
CN102199183B (zh) * 2010-03-26 2013-12-18 北京大学 环二鸟苷酸及其类似物和制备方法
CN101843899B (zh) * 2010-05-24 2012-11-07 中国人民解放军第三军医大学 耐甲氧西林金黄色葡萄球菌（mrsa）重组多亚单位基因工程疫苗及其制备方法
WO2012021554A1 (en) * 2010-08-09 2012-02-16 Yale University Cyclic di-gmp-ii riboswitches, motifs, and compounds, and methods for their use
US8450293B2 (en) 2010-08-10 2013-05-28 Rutgers, The State University Of New Jersey Synthesis and characterization of C8 analogs of c-di-GMP
CN104507538B (zh) 2012-06-08 2018-04-06 艾杜罗生物科技公司 癌症免疫疗法的组合物和方法
PL2931738T3 (pl) 2012-12-13 2019-07-31 Aduro Biotech, Inc. Kompozycje zawierające cykliczne dinukleotydy purynowe o zdefiniowanej stereochemii i sposoby ich otrzymywania i zastosowania
PT2934598T (pt) 2012-12-19 2018-07-24 Univ Texas Focalização farmacêutica de uma trajetória de sinalização de dinucleótido cíclico de mamífero
CN104152472A (zh) * 2012-12-28 2014-11-19 陶飞 一种双鸟苷酸环化酶基因、载体、工程菌及其应用
JP6153116B2 (ja) * 2013-01-09 2017-06-28 国立大学法人東北大学 トリアゾール連結型環状ジヌクレオチド類縁体
WO2014179335A1 (en) 2013-04-29 2014-11-06 Memorial Sloan Kettering Cancer Center Compositions and methods for altering second messenger signaling
WO2014179760A1 (en) 2013-05-03 2014-11-06 The Regents Of The University Of California Cyclic di-nucleotide induction of type i interferon
RS59500B1 (sr) 2013-05-18 2019-12-31 Aduro Biotech Inc Sastavi i metode za aktiviranje signaliziranja koje je zavisno od „stimulatora gena za interferon“
EP2996472B1 (en) * 2013-05-18 2019-03-27 Aduro Biotech, Inc. Compositions and methods for inhibiting "stimulator of interferon gene" dependent signalling
US9549944B2 (en) 2013-05-18 2017-01-24 Aduro Biotech, Inc. Compositions and methods for inhibiting “stimulator of interferon gene”—dependent signalling
EP3027227A4 (en) 2013-07-31 2018-05-23 Memorial Sloan Kettering Cancer Center Sting crystals and modulators
US9315523B2 (en) 2013-12-06 2016-04-19 Rutgers, The State University Of New Jersey Cyclic dinucleosides
PE20170198A1 (es) 2014-06-04 2017-04-08 Glaxosmithkline Ip Dev Ltd Dinucleotidos ciclicos como moduladores de sting
GB201501462D0 (en) 2015-01-29 2015-03-18 Glaxosmithkline Ip Dev Ltd Novel compounds
HK1248603A1 (zh) 2015-03-10 2018-10-19 Aduro Biotech, Inc. 用於活化"干扰素基因的刺激剂"依懒性信号传导的组合物和方法
TWI704154B (zh) 2015-12-03 2020-09-11 英商葛蘭素史克智慧財產發展有限公司 新穎化合物
SG10201912074PA (en) 2016-03-18 2020-02-27 Immune Sensor Llc Cyclic di-nucleotide compounds and methods of use
WO2018009466A1 (en) 2016-07-05 2018-01-11 Aduro Biotech, Inc. Locked nucleic acid cyclic dinucleotide compounds and uses thereof
WO2018100558A2 (en) 2016-12-01 2018-06-07 Takeda Pharmaceutical Company Limited Cyclic dinucleotide
WO2019043634A2 (en) * 2017-08-30 2019-03-07 Beijing Xuanyi Pharmasciences Co., Ltd. CYCLIC DI-NUCLEOTIDES AS STIMULATORS OF INTERFERON GENE MODULATORS
JP7195317B2 (ja) 2017-11-10 2022-12-23 武田薬品工業株式会社 Ｓｔｉｎｇ調節剤化合物、ならびに製造及び使用する方法
US11541105B2 (en) 2018-06-01 2023-01-03 The Research Foundation For The State University Of New York Compositions and methods for disrupting biofilm formation and maintenance
WO2020031083A1 (en) * 2018-08-06 2020-02-13 KHAN, Khalid Antimicrobial formulations comprising vancomycin or tobramycin
JP7621974B2 (ja) 2019-05-09 2025-01-27 アリゴス セラピューティクス インコーポレイテッド Ｓｔｉｎｇモジュレータとしての修飾環状ジヌクレオシド化合物
CN114085887A (zh) * 2020-08-25 2022-02-25 中国科学院大连化学物理研究所 一种基于仿生微球的铜绿假单胞菌耐药浓度的检测方法
JP7397996B2 (ja) 2020-11-09 2023-12-13 武田薬品工業株式会社 抗体薬物コンジュゲート
CN114099657B (zh) * 2021-11-04 2022-05-17 暨南大学 一种溶藻弧菌减毒活疫苗及其制备方法与应用
KR102551061B1 (ko) * 2022-05-26 2023-07-03 중앙대학교 산학협력단 Saha를 유효성분으로 포함하는 살모넬라 속 균주에 의한 바이오필름 생성 저해용 조성물
CN118956719B (zh) * 2024-07-31 2025-05-09 武汉市仪泰环境科技有限公司 一种毒性检测中加快微生物挂膜的方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5268274A (en) * 1989-04-12 1993-12-07 Cetus Corporation Methods and nucleic acid sequences for the expression of the cellulose synthase operon
AU1672492A (en) * 1991-05-03 1992-12-21 University Technologies International Inc. Biofilm reduction method
GB2257704B (en) 1991-07-18 1995-03-01 Erba Carlo Spa Cyclic oligonucleotides phosphorothioates
US20020091074A1 (en) * 2000-09-20 2002-07-11 Wooley Richard E. Medical compositions, dressings and methods for treating microbial infections of skin lesions
US20020169288A1 (en) * 2001-03-15 2002-11-14 Magnus Hook Collagen-binding adhesin from staphylococcus epidermidis and method of use
JP2002302404A (ja) * 2001-04-02 2002-10-18 Shiseido Co Ltd 抗菌防黴助剤
US7189351B2 (en) * 2001-10-25 2007-03-13 Spherix Incorporated D-tagatose as an anti-biofilm agent

Also Published As

Publication number Publication date
IL173065A0 (en) 2006-06-11
US20070244059A1 (en) 2007-10-18
WO2005030186A3 (en) 2005-07-14
JP2007500697A (ja) 2007-01-18
AU2004275696B2 (en) 2010-02-18
AU2004275696A1 (en) 2005-04-07
WO2005030186A2 (en) 2005-04-07
EP1651242A2 (en) 2006-05-03
US8367716B2 (en) 2013-02-05
CA2533873A1 (en) 2005-04-07

Similar Documents

Publication Publication Date Title
US8367716B2 (en) Method for attentuating virulence of microbial pathogens and for inhibiting microbial biofilm formation
Langendonk et al. The building blocks of antimicrobial resistance in Pseudomonas aeruginosa: implications for current resistance-breaking therapies
Nasrollahian et al. A review of the mechanisms that confer antibiotic resistance in pathotypes of E. coli
Totsika et al. Uropathogenic Escherichia coli mediated urinary tract infection
Sun et al. Fatty acids regulate stress resistance and virulence factor production for Listeria monocytogenes
Mitchell et al. Staphylococcus aureus sigma B-dependent emergence of small-colony variants and biofilm production following exposure to Pseudomonas aeruginosa 4-hydroxy-2-heptylquinoline-N-oxide
Zheng et al. Diclazuril inhibits biofilm formation and hemolysis of Staphylococcus aureus
Fothergill et al. Novel therapeutic strategies to counter Pseudomonas aeruginosa infections
Honma et al. Role of a Tannerella forsythia exopolysaccharide synthesis operon in biofilm development
Vieira et al. Campylobacter–acanthamoeba interactions
Antonello et al. Zidovudine in synergistic combination with fosfomycin: an in vitro and in vivo evaluation against multidrug-resistant Enterobacterales
Klahn et al. New structural templates for clinically validated and novel targets in antimicrobial drug research and development
Martinez Mechanisms of action and of resistance to quinolones
Jolivet‐Gougeon et al. Bacterial Persistence in Biofilms and Antibiotics: Mechanisms Involved
Kar et al. Quorum sensing mediated attenuation of biofilm formation and virulence traits in Staphylococcus aureus by trigonelline
RoyChowdhury et al. Colistin resistance in the era of antimicrobial resistance: challenges and strategic countermeasures
Wagley et al. A proteasome inhibitor produced by Burkholderia pseudomallei modulates intracellular growth
Bai et al. Functional characterization of pfm in protein secretion and lung infection of Pseudomonas aeruginosa
Ravishankar Investigation of antibiofilm and antivirulence activity of 5-fluorocytosine in Escherichia coli
Elkrewi Investigating the prevalence and genetic basis of resistance to the antimicrobial agents bacitracin, nitrofurantoin and silver in key pathogenic bacteria
Krath Investigation of a cryptic aminoglycoside resistance gene in Salmonella Enterica subspecies Enterica Serovar typhimurium
Wilkinson Biofilm formation and antibiotic resistance on alginate beads, of Staphylococcus aureus and other health care associated bacterial species
Rothstein et al. Rifalazil retains activity against rifampin-resistant mutants of Chlamydia pneumoniae
Jean Characterizarion of the regulation and function of Neisseria gonorrhoeae TonB-dependent transporters: TdfG, TdfH and TdfJ
Vieira Acanthamoeba as a Model for the Investigation of the Molecular Mechanisms of Campylobacter jejuni Pathogenesis and Survival in the Environment

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed